CHMP empfiehlt die Zulassung von Johnson & Johnsons TALVEY®▼ (Talquetamab) plus Daratumumab zur Behandlung des rezidivierten/refraktären multiplen Myeloms in einer früheren Therapielinie

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed/refractory multiple myeloma in an earlier treatment line (second-line). The MonumenTAL-3 Phase III trial demonstrated significant improvements in progression-free survival (81% at 24 months) and overall survival (89% at 24 months) compared to the control arm, with safety profiles consistent with individual monotherapies.